These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

299 related articles for article (PubMed ID: 35687210)

  • 1. P2 purinergic receptor dysregulation in urologic disease.
    Maynard JP; Sfanos KS
    Purinergic Signal; 2022 Sep; 18(3):267-287. PubMed ID: 35687210
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alterations in P2X and P2Y purinergic receptor expression in urinary bladder from normal cats and cats with interstitial cystitis.
    Birder LA; Ruan HZ; Chopra B; Xiang Z; Barrick S; Buffington CA; Roppolo JR; Ford AP; de Groat WC; Burnstock G
    Am J Physiol Renal Physiol; 2004 Nov; 287(5):F1084-91. PubMed ID: 15251862
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular and Pharmacological Evidence for the Expression of Multiple Functional P2 Purinergic Receptors in Human Adipocytes.
    Rossato M; Favaretto F; Granzotto M; Crescenzi M; Boscaro A; Di Vincenzo A; Capone F; Dalla Nora E; Zabeo E; Vettor R
    Molecules; 2022 Mar; 27(6):. PubMed ID: 35335277
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Purinergic signaling in kidney disease.
    Menzies RI; Tam FW; Unwin RJ; Bailey MA
    Kidney Int; 2017 Feb; 91(2):315-323. PubMed ID: 27780585
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Purinergic (P2) receptor control of lower genitourinary tract function and new avenues for drug action: an overview.
    Gur S; Kadowitz PJ; Hellstrom WJ
    Curr Pharm Des; 2007; 13(31):3236-44. PubMed ID: 18045173
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Altered ATP-sensitive P2 receptor subtype expression in the Han:SPRD cy/+ rat, a model of autosomal dominant polycystic kidney disease.
    Turner CM; Ramesh B; Srai SK; Burnstock G; Unwin RJ
    Cells Tissues Organs; 2004; 178(3):168-79. PubMed ID: 15655334
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization of calcium-independent purinergic receptor-mediated apoptosis in hormone-refractory prostate cancer.
    Shabbir M; Ryten M; Thompson C; Mikhailidis D; Burnstock G
    BJU Int; 2008 Feb; 101(3):352-9. PubMed ID: 18005209
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The P2 purinoceptors in prostate cancer.
    Wang Z; Zhu S; Tan S; Zeng Y; Zeng H
    Purinergic Signal; 2023 Mar; 19(1):255-263. PubMed ID: 35771310
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Potential therapeutic targets for ATP-gated P2X receptor ion channels.
    Li Z; Liang D; Chen L
    Assay Drug Dev Technol; 2008 Apr; 6(2):277-84. PubMed ID: 18471080
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Functional expression of purinergic P2 receptors and transient receptor potential channels by the human urothelium.
    Shabir S; Cross W; Kirkwood LA; Pearson JF; Appleby PA; Walker D; Eardley I; Southgate J
    Am J Physiol Renal Physiol; 2013 Aug; 305(3):F396-406. PubMed ID: 23720349
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cross talk between P2 purinergic receptors modulates extracellular ATP-mediated interleukin-10 production in rat microglial cells.
    Seo DR; Kim SY; Kim KY; Lee HG; Moon JH; Lee JS; Lee SH; Kim SU; Lee YB
    Exp Mol Med; 2008 Feb; 40(1):19-26. PubMed ID: 18305394
    [TBL] [Abstract][Full Text] [Related]  

  • 12. P2 purinergic receptors signal to STAT3 in astrocytes: Difference in STAT3 responses to P2Y and P2X receptor activation.
    Washburn KB; Neary JT
    Neuroscience; 2006 Oct; 142(2):411-23. PubMed ID: 16905269
    [TBL] [Abstract][Full Text] [Related]  

  • 13. P2-type purinergic signaling in the regulation of pancreatic β-cell functional plasticity as a promising novel therapeutic approach for the treatment of type 2 diabetes?
    Mesto N; Movassat J; Tourrel-Cuzin C
    Front Endocrinol (Lausanne); 2022; 13():1099152. PubMed ID: 37065173
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ATP and P2X purinoceptors in urinary tract disorders.
    Ford AP; Cockayne DA
    Handb Exp Pharmacol; 2011; (202):485-526. PubMed ID: 21290240
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Extracellular Nucleotides and P2 Receptors in Renal Function.
    Vallon V; Unwin R; Inscho EW; Leipziger J; Kishore BK
    Physiol Rev; 2020 Jan; 100(1):211-269. PubMed ID: 31437091
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The P2Y2 receptor sensitizes mouse bladder sensory neurons and facilitates purinergic currents.
    Chen X; Molliver DC; Gebhart GF
    J Neurosci; 2010 Feb; 30(6):2365-72. PubMed ID: 20147562
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The dark side of extracellular ATP in kidney diseases.
    Solini A; Usuelli V; Fiorina P
    J Am Soc Nephrol; 2015 May; 26(5):1007-16. PubMed ID: 25452669
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Purinergic receptor-mediated effects of ATP in high-grade bladder cancer.
    Shabbir M; Ryten M; Thompson C; Mikhailidis D; Burnstock G
    BJU Int; 2008 Jan; 101(1):106-12. PubMed ID: 17941929
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Extracellular nucleotides differentially regulate interleukin-1beta signaling in primary human astrocytes: implications for inflammatory gene expression.
    John GR; Simpson JE; Woodroofe MN; Lee SC; Brosnan CF
    J Neurosci; 2001 Jun; 21(12):4134-42. PubMed ID: 11404398
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Purinergic signalling in the urinary tract in health and disease.
    Burnstock G
    Purinergic Signal; 2014 Mar; 10(1):103-55. PubMed ID: 24265069
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.